34 related articles for article (PubMed ID: 38593345)
21. Advancing therapeutics using antibody-induced dimerization of receptor tyrosine phosphatases.
Tremblay ML
Genes Dev; 2023 Aug; 37(15-16):678-680. PubMed ID: 37673461
[TBL] [Abstract][Full Text] [Related]
22. Heparan sulfate proteoglycans and cancer.
Blackhall FH; Merry CL; Davies EJ; Jayson GC
Br J Cancer; 2001 Oct; 85(8):1094-8. PubMed ID: 11710818
[TBL] [Abstract][Full Text] [Related]
23. Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.
Farach-Carson MC; Warren CR; Harrington DA; Carson DD
Matrix Biol; 2014 Feb; 34():64-79. PubMed ID: 24001398
[TBL] [Abstract][Full Text] [Related]
24. Heparan Sulfate in the Tumor Microenvironment.
Bartolini B; Caravà E; Caon I; Parnigoni A; Moretto P; Passi A; Vigetti D; Viola M; Karousou E
Adv Exp Med Biol; 2020; 1245():147-161. PubMed ID: 32266657
[TBL] [Abstract][Full Text] [Related]
25. Tenascin-contactin/F11 interactions: a clue for a developmental role?
Vaughan L; Weber P; D'Alessandri L; Zisch AH; Winterhalter KH
Perspect Dev Neurobiol; 1994; 2(1):43-52. PubMed ID: 7530143
[TBL] [Abstract][Full Text] [Related]
26. Heparan sulfate in the nucleus and its control of cellular functions.
Stewart MD; Sanderson RD
Matrix Biol; 2014 Apr; 35():56-9. PubMed ID: 24309018
[TBL] [Abstract][Full Text] [Related]
27. Heparan sulfate fibroblast growth factor receptor complex: structure-function relationships.
McKeehan WL; Kan M
Mol Reprod Dev; 1994 Sep; 39(1):69-81; discusison 81-2. PubMed ID: 7999363
[TBL] [Abstract][Full Text] [Related]
28. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies.
Sanderson RD; Yang Y; Kelly T; MacLeod V; Dai Y; Theus A
J Cell Biochem; 2005 Dec; 96(5):897-905. PubMed ID: 16149080
[TBL] [Abstract][Full Text] [Related]
29. Specific structural features of syndecans and heparan sulfate chains are needed for cell signaling.
Lopes CC; Dietrich CP; Nader HB
Braz J Med Biol Res; 2006 Feb; 39(2):157-67. PubMed ID: 16470302
[TBL] [Abstract][Full Text] [Related]
30. Cancer-associated point mutations within the extracellular domain of PTPRD affect protein stability and HSPG interaction.
Matsui Y; Imai A; Izumi H; Yasumura M; Makino T; Shimizu T; Sato M; Mori H; Yoshida T
FASEB J; 2024 Apr; 38(7):e23609. PubMed ID: 38593345
[TBL] [Abstract][Full Text] [Related]
31. PTPRD: neurobiology, genetics, and initial pharmacology of a pleiotropic contributor to brain phenotypes.
Uhl GR; Martinez MJ
Ann N Y Acad Sci; 2019 Sep; 1451(1):112-129. PubMed ID: 30648269
[TBL] [Abstract][Full Text] [Related]
32. [Morphology of basement membrane and associated matrix proteins in normal and pathological tissues].
Nerlich A
Veroff Pathol; 1995; 145():1-139. PubMed ID: 8638427
[TBL] [Abstract][Full Text] [Related]
33. Receptor tyrosine kinases and heparan sulfate proteoglycans: Interplay providing anticancer targeting strategies and new therapeutic opportunities.
Lanzi C; Cassinelli G
Biochem Pharmacol; 2020 Aug; 178():114084. PubMed ID: 32526230
[TBL] [Abstract][Full Text] [Related]
34. Protein tyrosine phosphatase σ in proteoglycan-mediated neural regeneration regulation.
Chien PN; Ryu SE
Mol Neurobiol; 2013 Feb; 47(1):220-7. PubMed ID: 22956273
[TBL] [Abstract][Full Text] [Related]
[Previous] [New Search]
